20 results about "Cytokine expression" patented technology

The invention discloses application of a pain and diarrhea prescription to regulation and control of a BLP + macrophage subgroup to treat IBS-D. The pain and diarrhea prescription contains a liver soothing component (6-10 parts of pericarpium citri reticulatae and 6-10 parts of radix saposhnikoviae) and a spleen tonifying component (10-15 parts of rhizoma atractylodis macrocephalae and 10-15 parts of radix paeoniae alba) or a combination of the liver soothing component and the spleen tonifying component according to the ratio of 1: (1-2). By promoting the expression of anti-inflammatory cytokines IL-10 and TGF-beta, inhibiting the expression of pro-inflammatory cytokines IL-6 and TNF-alpha, activating an AMPK signal channel, inhibiting an NF-kappa B signal channel and promoting the expression of colonic mucosal barrier indexes ZO1 and OCLN, a colonic mucosal barrier is repaired, and the symptoms of IBS-D abdominal pain and diarrhea are relieved. The invention also provides a pharmaceutical composition containing the key active component, and the dosage forms comprise an aqueous solution, a tablet and the like. The traditional Chinese medicine composition solves the problems of large toxic and side effects, poor compliance and unknown mechanism in the existing IBS-D treatment, is definite and safe in curative effect, and has important clinical value and scientific significance.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

The invention belongs to the field of biotechnology and tumor immunotherapy, and particularly relates to a cancer vaccine based on attenuated listeria monocytogenes (LADS) and application of the cancer vaccine. Specifically, wild listeria monocytogenes (e.g., EGD-e) or attenuated listeria monocytogenes (LADS) are taken as an original strain, and an hly gene sequence or a fragment thereof in the original strain is replaced with polynucleotide of a fusion protein coding sequence containing LLO mutants (LLON478A + V479A) and TT856-1313, so that the recombinant attenuated listeria monocytogenes strain is obtained. Compared with wild listeria monocytogenes, the recombinant attenuated listeria monocytogenes strain has the advantages that the growth activity is not obviously changed, but the toxicity is obviously reduced; the polypeptide has cell infection ability, but has biological safety in a body and tends to colonize tumor tissue. Furthermore, the recombinant attenuated listeria monocytogenes strain can effectively inhibit the growth of cervical cancer and colon cancer, and can significantly induce immune response in a tumor microenvironment (e.g., significantly enhance cytokine expression).

A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The invention discloses an application of Rubiasin A in preparation of a medicine for preventing and treating lung injury. The invention proposes and verifies that Rubiasin A can achieve the effect of protecting the activity of pulmonary epithelial cells through the synergistic effect in three directions of relieving oxidative stress injury, inhibiting expression of pro-inflammatory cytokines and recovering mitochondrial functions of cells for the first time, so that acute lung injury is effectively relieved, and the Rubiasin A is a natural medicine with great application potential.

The invention discloses an immune cell counting detection method, and belongs to the technical field of immune cell detection. According to the invention, the problem of one-sidedness of the existing detection method is solved, the immune assessment is divided into three levels, and the first level structure detects the proportion and absolute count of the basal lymphocyte subpopulation; the secondary structure deeply analyzes functional subtypes of T cells, including Th1 / Th2 / Th17, initial / memory / activated T cells and regulatory T cells; the tertiary structure is used for evaluating cytokine expression and immune checkpoint molecules; performing multi-parameter detection on the same biological sample through optimized multicolor flow cytometry, and generating a comprehensive immune assessment report; therefore, the whole state and potential problems of the immune system can be intuitively reflected, popularization and application in a clinical examination laboratory are facilitated, comprehensive and deep immune information from the number of cells to the functional state is clinically provided, and the method has important value for diagnosis, treatment monitoring and prognosis evaluation of clinical immune related diseases.

The invention relates to the technical field of medicine, in particular to application of a compound in treatment of psoriasis, the compound is an AMPK activator Aldometanib, and the chemical structural formula of the compound is as shown in Figure 1. The research result shows that the Aldometanib can effectively relieve the psoriasis-like phenotype of mice, the erythema of the mice is converted from bright red to light red, the area is reduced, silver-white scales attached to the skin surface are thinned, and the psoriasis area and severity index (PASI) score is remarkably reduced. The mouse back skin lesion tissue is subjected to HE dyeing, the visible epidermis thickness is recovered to be close to the normal level through microscopic observation, inflammatory cell infiltration lesions on the superficial layer of dermis and around blood vessels are reduced, and the number is remarkably reduced. A mouse serum ELISA detection result shows that the expression of pro-inflammatory cytokines TNF alpha, IL-1beta and IL-6 is reduced. The Aldometanib disclosed by the invention is remarkable in anti-psoriasis effect, safe and non-toxic, and is expected to become a novel therapeutic drug for psoriasis.

The invention belongs to the technical field of biology, and particularly relates to application of PDPN (Podoplanin) in preparation of a medicine for treating viral myocarditis. More specifically, the invention provides a novel immunogenic peptide fragment PDPN-TE12 aiming at PDPN, a coding sequence of the novel immunogenic peptide fragment PDPN-TE12, a pharmaceutical composition containing the novel immunogenic peptide fragment PDPN-TE12, and application of the novel immunogenic peptide fragment PDPN-TE12 in prevention and / or treatment of inflammatory cardiomyopathy such as viral myocarditis. Experimental results show that the polypeptide PDPN-TE12 can significantly relieve myocardial damage of mice with viral myocarditis and inhibit inflammatory cell infiltration and inflammatory cytokine expression, so that the polypeptide PDPN-TE12 can be used as a potential drug for treating viral myocarditis, and a new candidate strategy is provided for precise targeted therapy of the disease.

The application discloses application of a large-mouth black bass stomach polypeptide in preparation of an antioxidant and / or immunoregulation product, relates to the field of bioactive peptides, and is characterized in that the large-mouth black bass stomach polypeptide is a polypeptide product obtained by alkaline protease enzymolysis of large-mouth black bass stomach, and components with molecular weights less than 3000 Da account for more than 98% of the total peptide amount. The polypeptide has significant DPPH free radical, hydroxyl free radical and ABTS cationic free radical scavenging capacity and reducing capacity, can promote macrophage proliferation, enhance phagocytosis, promote nitric oxide secretion, up-regulate immune-related cytokine expression, and play an immunoregulation role through activation of P38 and P44 MAPK signal pathways. The application realizes high-value utilization of large-mouth black bass processing by-products, has high product safety, and has a wide application prospect.

The invention discloses an application of a PD-L1 single-domain antibody in preparation of a preparation for promoting hair growth or preventing and treating alopecia, belongs to the technical field of biological medicines, and particularly discloses an effect of the PD-L1 single-domain antibody in regulation and control of expression of cytokines IL-6 and Leptin so as to activate a JAK-STAT signal channel and provides a new preparation source for treatment of non-scar alopecia. The invention further provides a preparation containing the PD-L1 single-domain antibody, the side effect of an existing medicine for treating alopecia can be overcome, the treatment effect is good, and after a subject takes the medicine for 3-4 times and 8 weeks after the medicine is stopped, hair growth at the original alopecia position still continues.

The application discloses a preparation method and application of a natural active ingredient compound nanogel agent for animals, and belongs to the technical field of veterinary drug preparations. The natural active ingredient compound nanogel agent disclosed by the application is composed of natural active ingredients, a gel matrix and additional agents, is reasonable in formula, simple in process, stable in property, convenient to use and safe and long-acting. The natural active ingredient compound nanogel agent contains two synergistically acting natural active ingredients, can inhibit the proliferation of endometritis pathogenic bacteria such as staphylococcus aureus and streptococcus, and reduce the expression of pro-inflammatory cytokines at an inflammation site; meanwhile, the natural active ingredient compound nanogel agent has a certain slow-release capacity, slowly releases natural active ingredient nanoparticles easy to be taken by cells, can realize long-time residence and high-efficiency absorption of drugs at a drug administration site, and thus can enhance the action time, reduce the drug administration frequency and improve the curative effect.

Provided is a bacterial strain, the bacterial strain being a bacterial strain of Odoribacter splanchnicus, and the bacterial strain having a 16S rRNA having a nucleotide sequence as shown in SEQ ID NO: 3, or a 16S rRNA having at least 95% sequence identity thereto. The bacterial strain can promote macrophage differentiation, induce increased inflammatory cytokine expression, promote IFNβ transcription activity, and enhance immune activity. In addition, the bacterial strain can produce short-chain fatty acids including acetic acid, and inhibit histone deacetylase activity. The bacterial strain inhibits the growth of tumor cells including liver cancer and colorectal cancer, and increases the response rate of lung cancer model mice to immunotherapy drugs. The bacterial strain has good application prospects in immunoregulation and in targeting tumors.

This invention provides a *Tai Sui* molecular ecological fluid extract obtained through specific fermentation, its preparation method, and its applications, belonging to the field of microbial fermentation technology. The invention uses a modified fermentation medium, introduces 5-8% CO2, maintains a dissolved oxygen concentration of 20-30%, and ferments at 30-32℃ for 90-180 days. After purification, the *Tai Sui* molecular ecological fluid extract is obtained. The *Tai Sui* molecular ecological fluid prepared using the method provided by this invention significantly increases the content of active ingredients that alleviate symptoms of chronic obstructive pulmonary disease (COPD). Furthermore, this invention verifies through in vitro cell experiments that the extract of this *Tai Sui* molecular ecological fluid has an inhibitory effect on the A549 cell line. Further animal experiments demonstrate that the extract can regulate the expression level of pro-inflammatory cytokines, thereby inhibiting lung inflammation, alleviating pathological damage to lung tissue, and improving local lung abnormalities.

The invention discloses a gene modification method of a fusion cytokine expression element and an immunotherapy application of the fusion cytokine expression element, and relates to the technical field of gene engineering and tumor immunotherapy. Comprising the following steps that A, a preset site is selected in a genome of a host cell, a first construct AL-B-C-B-AR is provided, AL is a first homologous arm located on the upstream of the preset site, AR is a second homologous arm located on the downstream of the preset site, B is an I-SceI incision enzyme recognition site, and C is a selection marker capable of being screened in the forward direction; inserting the B-C-B sequence into the predetermined loci by homologous directional integration to form a replaceable landing frame; wherein the preset site is preferably a safe port site and a non-essential intron segment of a target functional gene, the length of the homologous arm is preferably one hundred to one thousand bases, and after integration, the correctness of the 5'end and the 3 'end is confirmed through PCR breakpoint amplification and sequencing at the same time. The whole body exposure and toxicity are reduced.

The present invention belongs to the field of biology, and relates to a vector for expressing an RSPO1 protein and the use thereof. A plasmid containing a strong cell expression promoter is constructed, a 293 cell line with efficient and stable expression is obtained by means of screening, and a downstream purification process is optimized, thereby achieving mass production of an RSPO1 recombinant protein. The obtained 293 cell line with stable expression can be cultured in suspension in a serum-free medium for growth and cytokine expression and production, thus eliminating the influence of components in serum on the product quality. Moreover, the production volume can be scaled up to 2 L, 10 L or even 300 L, eradicating the limitations of the small volume of a plate culture system. In addition, the operations of plasmid extraction and transfection are omitted from production, which can reduce the batch-to-batch variation in cytokine expression, laying a foundation for large-scale expression.

The present invention relates to a composition comprising a heterotrophic skin bacterium and / or heterotrophic skin bacterial extract for use in the modulation of cytokine expression in a skin cell. The composition is particularly suited for use in the prevention and / or treatment of skin damage caused by UV light and use in treating skin conditions such as polymorphous light eruption (PLE).

Provided herein is an immune cell expressing a recombinant IL-2 or IL-2 mutein, wherein the immune cell is a natural killer cells (e.g., a cord blood derived NK (CB-NK) cell) or a γδ T cell, and wherein the IL-2 mutein has reduced binding to IL2 receptor (IL2R) (e.g., IL2Rβ). These immune cells can also be used in conjunction with cells genetically engineered with chimeric antigen receptors (CARs). Also provided are methods of modulating immune function by administering said immune cell, and methods of treating cancer, for example, acute myeloid leukemia.